The Latest Breaking News from CureVac

Barely a month goes by without headlines announcing yet another advancement in cancer vaccines.

Using the same mRNA technology as COVID vaccines, cancer vaccines are an emerging personalised treatment for cancer.

  CureVac (NASDAQ:CVAC) will host a conference call at 09:00 AM ET on April 28, 2022, to discuss Q4 2021 earnings results. How to Attend CureVac (CVAC) Conference Call Follow this link to access the live webcast.

Germany has signed a contract with CureVac BV (NASDAQ:CVAC) and its partner GlaxoSmithKline plc (NYSE:GSK) for domestically produced mRNA vaccines to bolster supplies for pandemic preparedness. The five-year contract allows for the production of up to 80 million doses at short notice until 2029, CureVac said, adding that those doses could be for the remainder of…

CureVac N.V. (NASDAQ:CVAC) dosed the first participant in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed with GlaxoSmithKline plc (NYSE:GSK).  The clinical trial is expected to provide valuable data to evaluate further the performance of CureVac’s second-generation mRNA backbone, which has the potential to be applied broadly in future vaccines against…

There is limited upside from CureVac BV’s (NASDAQ: CVAC) COVID-19 vaccine and there are few catalysts from the rest of the company’s pipeline in 2022, according to BofA Securities.